3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
9
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Diseases
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Cisplatin
274
pembrolizumab
229
Radiotherapy
166
Cetuximab
163
Carboplatin
122
Docetaxel
109
Paclitaxel
94
Fluorouracil
94
Nivolumab
84
Radiotherapy, Intensity-Modulated
78
Magnetic Resonance Spectroscopy
39
durvalumab
35
Radiation
32
Surgical Procedures, Operative
31
Drug Therapy
30
Radiosurgery
25
Erlotinib Hydrochloride
25
Biopsy
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Platinum
22
Specimen Handling
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Capecitabine
19
tremelimumab
18
Ipilimumab
18
Gemcitabine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Cell Carcinoma of Head and Neck
×
Imlunestrant
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled